Recent blog posts
Cabotamig Biologics Sequence Review Report 2026: CDH17 × CD3E Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Cabotamig Biologics Sequence Review Report 2026: CDH17 × CD3E Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cabotamig, an antibody targeting CDH17 × CD3E.
Read →
Aldastotug Biologics Sequence Review Report 2026: SIGLEC15 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Aldastotug Biologics Sequence Review Report 2026: SIGLEC15 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Aldastotug, an antibody targeting SIGLEC15.
Read →
Ansipastobart Biologics Sequence Review Report 2026: CD73 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Ansipastobart Biologics Sequence Review Report 2026: CD73 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ansipastobart, an antibody targeting CD73.
Read →
Torvutatug Biologics Sequence Review Report 2026: Folate receptor alpha Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Torvutatug Biologics Sequence Review Report 2026: Folate receptor alpha Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Torvutatug, an antibody targeting Folate receptor alpha.
Read →
Solnerstotug Biologics Sequence Review Report 2026: VSIR Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Solnerstotug Biologics Sequence Review Report 2026: VSIR Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Solnerstotug, an antibody targeting VSIR.
Read →
Sutacimig Biologics Sequence Review Report 2026: F7a × TREML1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Sutacimig Biologics Sequence Review Report 2026: F7a × TREML1 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sutacimig, an antibody targeting F7a × TREML1.
Read →
Spevatamig Biologics Sequence Review Report 2026: IAP × Claudin 18.2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Spevatamig Biologics Sequence Review Report 2026: IAP × Claudin 18.2 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Spevatamig, an antibody targeting IAP × Claudin 18.2.
Read →
Pamlectabart Biologics Sequence Review Report 2026: BCMA × CD3E Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Pamlectabart Biologics Sequence Review Report 2026: BCMA × CD3E Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pamlectabart, an antibody targeting BCMA × CD3E.
Read →
Peluntamig Biologics Sequence Review Report 2026: IAP × DLL3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Peluntamig Biologics Sequence Review Report 2026: IAP × DLL3 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Peluntamig, an antibody targeting IAP × DLL3.
Read →
Solabafusp Biologics Sequence Review Report 2026: PD-L1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Solabafusp Biologics Sequence Review Report 2026: PD-L1 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Solabafusp, an antibody targeting PD-L1.
Read →
Imneskibart Biologics Sequence Review Report 2026: IL2RA Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Imneskibart Biologics Sequence Review Report 2026: IL2RA Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imneskibart, an antibody targeting IL2RA.
Read →
Greziprubart Biologics Sequence Review Report 2026: C5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Greziprubart Biologics Sequence Review Report 2026: C5 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Greziprubart, an antibody targeting C5.
Read →